This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, S. P.
Right arrow Articles by Dawson, T. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, S. P.
Right arrow Articles by Dawson, T. C.
Related Collections
Right arrow Respiratory Tract
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PEDIATRICS Vol. 110 No. 3 September 2002, pp. e38

ELECTRONIC ARTICLE

Nebulized Morphine as a Treatment for Dyspnea in a Child With Cystic Fibrosis

Steven P. Cohen, MD and Timothy C. Dawson, MD

From the Pain Management Center, Department of Anesthesiology, Walter Reed Army Medical Center, Washington, DC

--> Objective. To shed light on nebulized morphine, a new treatment for dyspnea in children with terminal lung disease.

Methods. A clinical case study was conducted on a patient in a tertiary care medical center.

Results. Nebulized morphine was administered in incremental doses ranging from 2.5 mg to 12.5 mg in a 10-year-old, 20-kg boy with end-stage cystic fibrosis. Before the nebulized morphine treatments were started, a dose of nebulized lidocaine failed to provide the patient with any relief. After each dose of morphine, the following parameters were recorded: visual analog "dyspnea" scores, vital signs, venous blood gases, and blood levels of morphine. The nebulized morphine was found to have a modest effect on the patient’s dyspnea, with no significant differences found between the varying doses. Venous carbon dioxide tension levels increased <4 mm Hg for all doses except 12.5 mg, for which there was a 9-mm Hg increase. Systemic blood levels of morphine were <10 ng/mL at all doses. The nebulized morphine did not cause any significant changes in blood pressure or heart rate for doses <12.5 mg.

Conclusions. Inhaled morphine was associated with a mild, beneficial effect on dyspnea, with minimal differences found between the lowest and highest doses. This "ceiling" effect may be the result of saturation of opioid receptors in the lung, the variable bioavailability of inhaled morphine, or a placebo response. More studies are needed to determine what, if any, the optimum dose of nebulized morphine is for children.

Key Words: cystic fibrosis • dyspnea • inhaled morphine • peripheral opioid receptors

Abbreviations: VAS, visual analog "dyspnea" scales • BP, blood pressure • HR, heart rate • RR, respiratory rate • PVCO2, venous carbon dioxide tension • PCA, patient-controlled analgesia device

Received for publication Jan 29, 2002; Accepted May 28, 2002.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?